Iovance Shares Hits 52-Week High After Offering Pricing, FDA Approvals
By Dean Seal
Shares of Iovance hit a 52-week high after the company's $211 million underwritten offering was priced and it announced key approvals from regulators for Amtagvi.
The stock jumped 47% to a high of $13.41 in early trading. Shares are up 50% year-to-date.
The biotechnology company said Tuesday morning that it would sell up to 23 million shares at $9.15 apiece, the same as Friday's closing price, in an offering set to close on Feb. 22.
Iovance also said Tuesday that the U.S. Food and Drug Administration has approved WuXi Advanced Therapies' Philadelphia site for the analytical testing and manufacturing of Amtagvi, Iovance's immunotherapy for patients with unresectable or metastatic melanoma who were previously treated with a PD-1 blocking antibody.
The company said just before the market closed last week that regulators had granted an accelerated approval to Amtagvi suspension for intravenous infusion.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
February 20, 2024 11:18 ET (16:18 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom